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The sensing of viral RNA by the host innate immune system is mediated by RIG-I and its partner PACT. In this
issue ofCell Host &Microbe, Luthra et al. (2013) show that the Ebola virus VP35 protein counteracts the action
of PACT at the cost of compromising its own function in viral replication.Host cells combat viral infection by mobi-
lizing an innate immune response medi-
ated by antiviral cytokines such as type
I interferons. This response can be trig-
gered by the recognition of invading viral
RNA by the prototypic cytoplasmic
sensor RIG-I together with its partners
and activators such as PACT (Kok et al.,
2011). PACT and its homolog TRBP are
multifunctional double-stranded RNA
(dsRNA)-binding proteins that also func-
tion in RNA silencing and the regulation
of protein kinase R (PKR) activity. To
what extent PACT participates in antiviral
response in a physiological context and
whether viruses have evolved counter-
measures to inhibit the activity of PACT
remain open questions in the field. In
this issue of Cell Host & Microbe, Basler
and colleagues report several missing
pieces in the puzzle. They showed that
Sendai virus was unable to induce inter-
ferons in Pact-deficient mouse embry-
onic fibroblasts. They also provided
evidence for the counteraction of PACT
by Ebola virus-encoded interferon-antag-
onizing protein VP35. Furthermore, their
characterization of the mutual antago-
nism between PACT and VP35 revealed
a balance of power in the host-Ebola
virus interaction (Luthra et al., 2013).
According to their model, VP35 binds to
and counteracts PACT in the activation
of type I interferon production, and in
turn PACT impedes the function of VP35
in viral RNA synthesis and replication
(Figure 1).
Ebola virus is a highly lethal pathogen.
Evasion of innate immunity is a major
mechanism by which Ebola virus causes
severe disease in human. VP35 is a
prominent Ebola virus virulence factor
that is both an essential cofactor of viralpolymerase and an interferon antagonist
that contributes to immune evasion. Tar-
geting of PACT by VP35 uncovers a new
viral countermeasure in the battle against
host innate antiviral response. Basler and
associates demonstrated that VP35
suppresses PACT-induced activation of
RIG-I by preventing PACT from interact-
ing with RIG-I (Luthra et al., 2013). Since
VP35 is structurally and functionally
related to other viral interferon-antago-
nizing and dsRNA-binding proteins such
as influenza A virus NS1, herpes simplex
virus type 1 Us11, and vaccinia virus
E3L, it will be of great interest to see
whether PACT targeting is a general
mechanism of immune evasion adopted
by multiple pathogenic viruses. Theoreti-
cally these viral proteins might operate in
the same way as VP35 if they could also
bind PACT. Indeed, both influenza NS1
and herpes Us11 are known to interact
with PACT (Li et al., 2006; Peters et al.,
2002), raising the possibility that they
might also prevent PACT from interact-
ing with and activating RIG-I. On the
other hand, although NS1 is not a
component of influenza viral polymerase,
it is also recruited to the polymerase
complex through an interaction with the
viral nucleoprotein NP (Robb et al.,
2011). Interestingly, PACT binds the PA
subunit of the influenza viral polymerase
and exhibits antiviral activity by perturb-
ing polymerase-mediated transcriptional
activity (Tafforeau et al., 2011). Thus,
the mutual antagonism between VP35
and PACT might represent a recurrent
theme in host-virus interaction. With
slight variations the theme could also
be envisioned in the context of other
viruses including influenza. In the context
of influenza, PACT could execute its anti-Cell Host & Microviral activity through at least two mecha-
nisms: activation of RIG-I-dependent
production of type I interferons and
perturbation of viral polymerase-medi-
ated viral RNA synthesis and replication.
In this regard, further investigations are
required to clarify the biological signifi-
cance of NS1-PACT and PACT-PA
interactions in suppressing influenza
virus replication and shaping the innate
immune response.
VP35 was demonstrated to suppress
PACT activity by preventing its interac-
tion with RIG-I (Luthra et al., 2013). Eluci-
dating how PACT activates RIG-I remains
the next challenge in the field. RIG-I is
strikingly similar to the RNase III family
endoribonuclease Dicer that also bears
a DEAD box RNA helicase domain.
Human Dicer has two dsRNA-binding
partners, TRBP and PACT (Kok et al.,
2007). The identification of the role of
PACT in the activation of RIG-I was
initially prompted by the activation of
Dicer by TRBP and PACT (Kok et al.,
2011). Understanding how TRBP and
PACT activate Dicer would also be
instructive in the analysis of PACT activa-
tion of RIG-I. Several recent studies have
shed light on the mechanistic details of
the roles of TRBP and PACT in Dicer
function. Interestingly, TRBP and PACT
display an ATP-independent and RNA
length-dependent diffusion activity exclu-
sively on dsRNA (Koh et al., 2013). TRBP
and its homologs in fruit flies are capable
of altering Dicer cleavage rate and site in
microRNA (miRNA) processing, leading
to the production of miRNAs of distinct
target specificities (Fukunaga et al.,
2012). In addition, TRBP and PACT exert
differential effects on Dicer and Ago2 in
the processing of miRNAs and shortbe 14, July 17, 2013 ª2013 Elsevier Inc. 5
Figure 1. Striking a Balance in Host-Ebola Virus Interaction
Ebola virus VP35 is a dsRNA-binding protein and an essential cofactor of the
viral polymerase complex, which also contains NP and L proteins. In this
context, VP35 functions to facilitate viral RNA synthesis and replication. On
the other hand, VP35 is an interferon-antagonizing protein that counteracts
PACT and RIG-I to inhibit the activation of interferon production. Ebola virus
suppression of PACT by VP35 comes at the cost of having VP35’s activity in
viral replication inhibited by PACT.
Cell Host & Microbe
Previewsinterfering RNAs (siRNAs).
They cooperate to determine
substrate selection, guide
strand selection, and cleav-
age specificity (Noland and
Doudna, 2013). In compari-
son with the influence of
TRBP and PACT on Dicer, it
will not be surprising if
PACT could function to
concentrate and select RNA
ligands for RIG-I. PACT
might also tip the balance
toward an RNA-induced
conformational change of
RIG-I, leading to its activa-
tion. It will be of particular in-
terest to investigate whether
PACT is capable of altering
the enzymatic and biological
activity of RIG-I, thus influen-
cing selection of partners
and activation of down-
stream effectors.
Both VP35 and PACT
are pleiotropic proteins that
engage multiple partners.
How they coordinate the
interactionwith different part-
ners spatially and temporallywithin the infected cells remains to be
clarified. Rescue experiments conducted
with Pact-deficient cells provide strong
support to the notion that VP35 suppres-
sion of interferon production is mediated
through PACT (Luthra et al., 2013). How-
ever, it will be important to explore
whether the interaction of VP35 with
PACT is also critical in the suppression
of PKR and Dicer activities. In addition,
further investigations are required to
determine whether some of the partners
of VP35 and PACT form multisubunit
complexes or if they are mutually exclu-
sive, as in the case of RIG-I and VP35 in
their interaction with PACT. Mass spec-
troscopic analysis of subcellular pro-
teomes and interactomes derived from
cytoplasmic, nuclear, and mitochondrial
fractions of infected cells collected at6 Cell Host & Microbe 14, July 17, 2013 ª201different phases of infection would reveal
key information concerning the dynamic
interaction of VP35 and PACT with their
partners. Determination of the affinity of
binding between different partners using
biochemical and biophysical methods
might also shed light on what binding
partners of VP35 and PACT would prevail
in the competition. A detailed analysis of
the results from biochemical fractionation
and protein dynamics will provide impor-
tant clues to the VP35 and PACT interac-
tome. For example, analysis of protein
complex formation would suggest new
directions to investigate whether and
how VP35 and PACT partners and homo-
logs such as PKR, TRBP, Dicer, MDA5,
and LGP2 might impact on the mutual
antagonism of VP35 and PACT. On the
other hand, in one simplemodel to explain3 Elsevier Inc.mutual antagonism of VP35
and PACT, the VP35-PACT
complex is sequestered in a
subcellular compartment or
is more prone to ubiquitina-
tion and proteosome-depen-
dent degradation, preventing
their interaction with respec-
tive partners such as viral
polymerase and RIG-I. Fur-
ther analysis of the fate of
VP35-PACT in infected cells
is therefore warranted. Get-
ting to the bottom of all these
questions will substantially
advance our understanding
of host-virus interaction and
innate antiviral response.
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